首页 工具
登录
全部产品 抑制剂&激动剂 化合物库 天然产物 技术服务 重组蛋白 会员中心 联系我们
购物车
抑制剂&激动剂 血管生成 凋亡 自噬 细胞周期 表观遗传 细胞骨架 DNA损伤和修复 内分泌与激素 G蛋白偶联受体 免疫与炎症 JAK/STAT信号通路 MAPK信号通路 离子通道 代谢 微生物学 神经科学
化合物库 活性化合物库 •   通用已知活性库 •   上市状态分类 •   疾病类型分类 •   通路靶点分类 天然产物库 •   高通量筛选天然产物库 •   特色天然产物库 •   天然产物衍生物库 Fragment片段库 •   通用片段库 •   特色片段库 类药性化合物库 •   多样性核心库Part2 •   多样性核心库Part1 化合物库深度定制
技术服务 计算机辅助药物设计 •   虚拟筛选 实体化合物活性筛选 •   分子结合&互作检测 药物设计和结构优化 天然产物 试剂盒 Cell Counting Kit-8 (CCK-8) Inhibitor Cocktails SYBR Green qPCR Master Mix (No ROX) 染料试剂 多肽产品 抗体抑制剂 PROTAC
重组蛋白 细胞因子和生长因子 •   细胞因子 •   生长因子 受体蛋白 •   Fc 受体 •   细胞因子和生长因子受体 •   受体酪氨酸激酶 CD 蛋白 •   T 细胞 CD 蛋白 •   B 细胞 CD 蛋白 免疫检查点蛋白 •   抑制性免疫检查点蛋白 •   刺激性免疫检查点蛋白 CAR-T 细胞治疗靶点蛋白 •   血液恶性肿瘤靶点蛋白 •   实体瘤靶点蛋白
信号通路 血管生成 凋亡 自噬 细胞周期 表观遗传 细胞骨架
DNA损伤和修复 内分泌与激素 G蛋白偶联受体 免疫与炎症 JAK/STAT信号通路 MAPK信号通路 离子通道
代谢 微生物学 神经科学 NF-κB信号通路 氧化还原 PI3K/Akt/mTOR信号通路 蛋白酶体
干细胞 蛋白酪氨酸激酶 泛素化 PROTAC 其他
活性化合物库 上市药物库 临床期小分子药物库 已知活性化合物库 FDA上市及药典收录分子库 抗癌药物库 抗病毒库 铁死亡化合物库
天然产物库 高通量筛选天然产物库 Ro5类药天然产物库 中药单体化合物库 糖类及苷类化合物库 稀有天然产物库 天然产物衍生物库 天然产物单体化合物库
Fragment片段库 高溶解性片段库 精选片段库 高溶解性多官能团片段化合物库 高溶解性卤化片段化合物库 药物片段库 Mini片段亲电杂环化合物库 高溶解性微型片段化合物库
类药性化合物库 多样性核心库Part2 多样性核心库Part1 药物靶点库 多样性核心预制库 Golden骨架库 Mini骨架库 化合物库深度定制
TargetMol Compound Library
天然产物库 高通量筛选天然产物库 特色天然产物库 天然产物衍生物库 虚拟筛选天然产物库
结构类型 萜类 类固醇 类黄酮 醌类 香豆素 木脂素 多糖和糖苷
苯丙烷 生物碱 酚类 其他
植物来源 列当科 水龙骨科 南洋杉科 报春花科 海金沙科 商陆科 买麻藤科
萝藦科 肉豆蔻科 鸭跖草科 交让木科 三白草科 海桐花科 五味子科 红厚壳科
莲叶桐科 胡桃科 石杉科 桔梗科 百合科 忍冬科 漆树科
计算机辅助药物设计 虚拟筛选 分子对接 反向找靶 分子动力学模拟
基于靶点筛选实体化合物活性筛选 分子结合&互作检测 酶学靶点活性检测 核受体靶点活性检测 GPCR靶点活性检测
基于表型筛选实体化合物活性筛选 细胞增殖检测 细胞周期检测 细胞凋亡检测 药代动力学研究
药物设计和结构优化 化合物定制合成 分子砌块 网络药理学平台 软件平台
细胞因子和生长因子 •   细胞因子 •   生长因子 受体蛋白 •   Fc 受体 •   细胞因子和生长因子受体
CD 蛋白 •   T 细胞 CD 蛋白 •   B 细胞 CD 蛋白 免疫检查点蛋白 •   抑制性免疫检查点蛋白 •   刺激性免疫检查点蛋白
CAR-T 细胞治疗靶点蛋白 •   血液恶性肿瘤靶点蛋白 •   实体瘤靶点蛋白 酶 •   氧化还原酶 •   转移酶
病毒蛋白 •   冠状病毒蛋白 •   流感病毒蛋白 荧光蛋白 其他蛋白

搜索结果

Search Results for " ki-ras "
Targets Recommended: Raf Ras

6

抑制剂 & 化合物

1

天然产物

60

重组蛋白

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。     QQ咨询       网站留言咨询

提交您的定制咨询

点击图片重新获取验证码
Cat. No. Product Name Target Signaling Pathways
T1892 Kobe2602

Raf; Ras GPCR/G Protein; MAPK
Kobe2602 是 Ras-Raf 相互作用抑制剂，具有抗癌化疗活性。它抑制 H-Ras·GTP 与 c-Raf-1 RBD 结合的Ki 值为 149 μM。
T7558 CID-1067700

2-[[(苯甲酰基氨基)硫代甲酰]氨基]-4,7-二氢-5,5-二甲基-5H-噻吩并[2,3-C]吡喃-3-羧酸

 Ras GPCR/G Protein; MAPK
CID-1067700 是泛 GTPase 抑制剂，可竞争性抑制大脑 7 (Rab7) 中的 Ras 相关蛋白，Ki 为 13 nM。
T1876 Kobe0065

Apoptosis; Raf; Ras Apoptosis; GPCR/G Protein; MAPK
Kobe0065 是一种新型 Ras-Raf 相互作用抑制剂，可完全抑制 H-Ras·GTP 与 c-Raf-1 RBD 的结合，Ki 值为 46±13 μM。
T6163 Salirasib

沙利雷塞,法尼基硫代水杨酸,Farnesyl Thiosalicylic Acid,S-Farnesylthiosalicylic acid,FTS

 Autophagy; Ras Autophagy; GPCR/G Protein; MAPK
Salirasib (Farnesyl Thiosalicylic Acid) 是一种有效的竞争性异戊二烯化蛋白甲基转移酶抑制剂，抑制 Ras 甲基化并具有潜在的抗肿瘤活性。
T70134 L-778123 Dihydrochloride

L-778123 is an inhibitor of FPTase and GGPTase-I, which was developed in part because it can completely inhibit Ki-Ras prenylation. The combination of L-778,123 and radiotherapy at dose level 1 showed acceptable toxicity in patients with locally advanced pancreatic cancer. Radiosensitization of a patient-derived pancreatic cancer cell line was observed.
T69826 U-0126

U0126 is a highly selective inhibitor of both MEK1 and MEK2, a type of MAPK/ERK kinase. It was found to functionally antagonize AP-1 transcriptional activity via noncompetitive inhibition of the dual specificity kinase MEK with IC50 of 72 nM for MEK1 and 58 nM for MEK2. U0126 inhibited anchorage-independent growth of Ki-ras-transformed rat fibroblasts by simultaneously blocking both extracellular signal-regulated kinase and mammalian target of rapamycin pathways.

化合物

Kobe2602
Cat.No: T1892
Synonym:
Target: Raf, Ras
CID-1067700
Cat.No: T7558
Synonym: 2-[[(苯甲酰基氨基)硫代甲酰]氨基]-4,7-二氢-5,5-二甲基-5H-噻吩并[2,3-C]吡喃-3-羧酸
Target: Ras
Kobe0065
Cat.No: T1876
Synonym:
Target: Apoptosis, Raf, Ras
Salirasib
Cat.No: T6163
Synonym: 沙利雷塞,法尼基硫代水杨酸,Farnesyl Thiosalicylic Acid,S-Farnesylthiosalicylic acid,FTS
Target: Autophagy, Ras
L-778123 Dihydrochloride
Cat.No: T70134
Synonym:
Target:
U-0126
Cat.No: T69826
Synonym:
Target:
Cat. No. Product Name Target Signaling Pathways
T16011 Manumycin A

Prostaglandin Receptor GPCR/G Protein; Immunology/Inflammation
Manumycin A is an antibiotic. Manumycin A induces apoptosis and exerts antitumor activity. Manumycin A inhibits exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling. Manumycin A acts as a selective, competitive inhibitor of

天然产物

Manumycin A
Cat.No: T16011
Synonym:
Target: Prostaglandin Receptor
Species：
Human (60)
Expression System：
HEK293 Cells (38)
E. coli (22)
Tag：
C-His-Avi (51)
N-His (5)
N-6xHis (2)
GST (1)
His, Avi (1)
Cat. No. Product Name Species Expression System
TMPY-01888 KRAS Protein,Human, Recombinant (Q61H, His)

KRAS2,C-K-RAS,Kirsten rat sarcoma...

 Human E. coli
KRAS Protein,Human, Recombinant (Q61H, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 22.5 kDa and the accession number is P01116-2.
TMPY-04116 KRAS Protein,Human,Recombinant(G12C & Q61H, His)

NS,CFC2,K-RAS4B,C-K-RAS,KRAS2,K-<...

 Human E. coli
KRAS Protein,Human,Recombinant(G12C & Q61H, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 23.3 kDa and the accession number is P01116-2.
TMPY-06056 KRAS Protein, Human, Recombinant (G12D, His)

KRAS1,K-RAS4B,Kirsten rat sarcoma...

 Human E. coli
KRAS Protein, Human, Recombinant (G12D, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 22 kDa and the accession number is P01116-2.
TMPY-04113 KRAS Protein,Human,Recombinant(G12D & Q61H, His)

Kirsten rat sarcoma viral oncogene homolog,KRAS...

 Human E. coli
KRAS Protein,Human,Recombinant(G12D & Q61H, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 23.3 kDa and the accession number is P01116-2.
TMPJ-00510 KRAS Protein, Human, Recombinant (G12C, His)

RASK2,c-K-ras,CFC2,KRAS2,Ki

Human E. coli
KRAS Protein, Human, Recombinant (G12C, His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 26 KDa and the accession number is AAH13572.1.
TMPJ-00511 KRAS Protein, Human, Recombinant (G12V, His)

KRAS2,RASK2,c-K-ras,Ki-<...

 Human E. coli
KRAS Protein, Human, Recombinant (G12V, His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 25-30 KDa and the accession number is AAH13572.1.
TMPK-01405 HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

KI-RAS,RASK2,K-Ras 2,MHC...

 Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01428 HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi)

CFC2,K-RAS4B,K-Ras 2,C-K-RAS,...

 Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01443 HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled

KRAS1,C-K-RAS,K-RAS4B,RALD,K-...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01450 HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated

KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01462 HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

K-RAS4A,K-RAS2A,CFC2,KRAS1,K-...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01511 HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

GTPase Kras,K-RAS4A,KI-RAS

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01460 HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

MHC,K-RAS2A,KI-RAS,K-RAS...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01427 HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

C-K-RAS,K-RAS4B,GTPase Kras,K-

Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01403 HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

K-Ras 2,KI-RAS,CFC2,KRAS...

 Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01399 HLA-A*11:01&B2M&KRAS WT (VVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

K-RAS2A,NS3,KRAS2,CFC2,K-RAS4B,GT...

 Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01404 HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated

NS,KRAS,KRAS1,KRAS2,MHC,RALD,K-

Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01479 HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

NS3,KRAS1,K-Ras 2,K-RAS2A,K-R...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01525 HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

CFC2,RALD,K-Ras 2,MHC,C-K-RAS,NS3,GTPase K...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01461 HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi)

C-K-RAS,KRAS,RASK2,K-Ras...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01434 HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi)

RASK2,CFC2,GTPase Kras,KRAS,K-

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01402 HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated

KRAS1,NS,CFC2,K-RAS4B,RASK2,K-

Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01430 HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

K-RAS2A,RALD,NS3,K-Ras 2,KI-R...

 Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01432 HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein, Human, MHC (His & Avi)

RASK2,K-RAS4A,K-RAS4B,KRAS

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01440 HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled

RASK2,KI-RAS,C-K-RAS,K

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01528 HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)

KRAS1,MHC,K-RAS2B,K-RAS4B,NS,GTPa...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01456 HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)

KRAS2,NS,MHC,C-K-RAS,KRAS1,K-...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01512 HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)

K-Ras 2,NS,NS3,K-RAS2B,CFC2,MHC,KRAS

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01465 HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi)

NS3,K-RAS2A,CFC2,KRAS,GTPase Kras...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01435 HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled

KRAS2,NS3,RASK2,KI-RAS,R...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01438 HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled

RASK2,KRAS2,KRAS1,MHC,C-K-RAS...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01507 HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi)

K-RAS2A,K-RAS4B,KI-RAS,R...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01408 HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated

RALD,KRAS1,KRAS2,K-RAS2B,CFC2,NS3...

 Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01401 HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)

MHC,CFC2,K-Ras 2,RALD,K-RAS4A,NS,RAS

Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01429 HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated

MHC,K-Ras 2,NS,K-RAS4A,KRAS,NS3,<...

 Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01488 HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)

K-RAS4A,MHC,GTPase Kras,K-Ras 2,K...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01451 HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)

NS3,K-RAS4A,K-Ras 2,NS,KRAS1,...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01529 HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi)

K-RAS4A,KRAS1,MHC,K-RAS2B,CFC2,GT...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01458 HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi)

K-Ras 2,GTPase Kras,KRAS2,MHC,K-<...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01463 HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi)

C-K-RAS,KI-RAS,KRAS1,K-<...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01518 HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi)

MHC,NS,KRAS1,K-RAS2A,GTPase Kras,...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01527 HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)

NS,RALD,C-K-RAS,RASK2,K-RAS2B,K

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01510 HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi)

NS,NS3,KRAS2,RASK2,MHC,RALD,K-Ras...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01433 HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer Protein, Human, MHC (His & Avi)

GTPase Kras,NS3,K-Ras 2,K-RAS2B,R...

 Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPY-06345 KRAS Protein, Human, Recombinant (His & Avi), Biotinylated

RASK2,K-RAS2A,RALD,C-K-RAS,NS3,

Human E. coli
KRAS Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in E. coli expression system with His and Avi tag. The predicted molecular weight is 23.78 kDa and the accession number is P01116-2.
TMPY-06138 KRAS Protein, Human, Recombinant (61Q, His)

Kirsten rat sarcoma viral oncogene homolog,K-RA...

 Human E. coli
KRAS Protein, Human, Recombinant (61Q, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 21.9 kDa and the accession number is P01116-2.
TMPK-01400 HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated

NS,KRAS1,RALD,K-RAS2A,K-RAS2B,K-<...

 Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01407 HLA-A*02:01&B2M&KRAS WT (KLVVVGAGGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated

KRAS2,RALD,C-K-RAS,NS3,MHC,CFC2,KRAS

Human E. coli
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
TMPK-01536 HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

NS3,MHC,KRAS,RALD,CFC2,K-RAS2B,GTPase K

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
TMPK-01464 HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated

C-K-RAS,K-RAS4A,GTPase Kras,K-

Human HEK293 Cells
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
------------------------ 更多 ------------------------

重组蛋白

KRAS Protein,Human, Recombinant (Q61H, His)
Cat.No: TMPY-01888
Species: Human
Expression System: E. coli
KRAS Protein,Human,Recombinant(G12C & Q61H, His)
Cat.No: TMPY-04116
Species: Human
Expression System: E. coli
KRAS Protein, Human, Recombinant (G12D, His)
Cat.No: TMPY-06056
Species: Human
Expression System: E. coli
KRAS Protein,Human,Recombinant(G12D & Q61H, His)
Cat.No: TMPY-04113
Species: Human
Expression System: E. coli
KRAS Protein, Human, Recombinant (G12C, His)
Cat.No: TMPJ-00510
Species: Human
Expression System: E. coli
KRAS Protein, Human, Recombinant (G12V, His)
Cat.No: TMPJ-00511
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
Cat.No: TMPK-01405
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01428
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled
Cat.No: TMPK-01443
Species: Human
Expression System: HEK293 Cells
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01450
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01462
Species: Human
Expression System: HEK293 Cells
HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01511
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01460
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01427
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
Cat.No: TMPK-01403
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS WT (VVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01399
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
Cat.No: TMPK-01404
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01479
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01525
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01461
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01434
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
Cat.No: TMPK-01402
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
Cat.No: TMPK-01430
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01432
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
Cat.No: TMPK-01440
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01528
Species: Human
Expression System: HEK293 Cells
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01456
Species: Human
Expression System: HEK293 Cells
HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01512
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01465
Species: Human
Expression System: HEK293 Cells
HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
Cat.No: TMPK-01435
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
Cat.No: TMPK-01438
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01507
Species: Human
Expression System: HEK293 Cells
HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01408
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
Cat.No: TMPK-01401
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
Cat.No: TMPK-01429
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01488
Species: Human
Expression System: HEK293 Cells
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01451
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01529
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01458
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01463
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01518
Species: Human
Expression System: HEK293 Cells
HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01527
Species: Human
Expression System: HEK293 Cells
HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01510
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer Protein, Human, MHC (His & Avi)
Cat.No: TMPK-01433
Species: Human
Expression System: HEK293 Cells
KRAS Protein, Human, Recombinant (His & Avi), Biotinylated
Cat.No: TMPY-06345
Species: Human
Expression System: E. coli
KRAS Protein, Human, Recombinant (61Q, His)
Cat.No: TMPY-06138
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
Cat.No: TMPK-01400
Species: Human
Expression System: E. coli
HLA-A*02:01&B2M&KRAS WT (KLVVVGAGGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01407
Species: Human
Expression System: E. coli
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01536
Species: Human
Expression System: HEK293 Cells
HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
Cat.No: TMPK-01464
Species: Human
Expression System: HEK293 Cells
--------- 更多 ---------
TargetMol®
关于我们 隐私声明 前沿资讯 相关条款
相关支持
联系我们 全球经销商 订购指南 技术支持
技术资源
产品目录 产品引用文献 信号通路 溶液计算器
订阅 TargetMol®
订阅以获得我们的产品更新和特惠活动!
获取我们的最新产品和特惠活动!
TargetMol®
相关支持
技术资源
我们的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。
Copyright © 2015-2024 TargetMol Chemicals Inc. All rights reserved. 沪ICP备20019793号-4 沪公网安备 31010602006700号 沪公网安备 31010602006700号
联系我们
400-820-0310
service@tsbiochem.com
2881945090（终端用户）
2885109491（经销商） 

上海市静安区江场三路238号8楼